A recent study demonstrated that at the early stage of NAFLD development LSECs exert anti-inflammatory effects through the suppression of leukocyte recruitment into hepatic sinusoids; this effect is mediated by reducing the expression of CCL2, CXCL10, and CXCL16. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatotic liver disease.